PROBLEM: During an influenza outbreak or pandemic, timely access to antivirals is essential to reduce disease severity and transmission. Best practices in antiviral procurement, storage, distribution, prescription and dispensing must be followed for prompt drug delivery. APPROACH: Mexico implemented a national pandemic preparedness plan in 2006 and created a strategic antiviral stockpile. Oseltamivir powder was stored centrally in bulk for distribution to all 31 states and the capital district during an influenza outbreak. LOCAL SETTING: San Luis Potosí, in northern Mexico, was one of the states most intensely affected by the 2009 H1N1 influenza outbreak. RELEVANT CHANGES: The oseltamivir powder was meant to be reconstituted locally but had to be reconstituted centrally during the 2009 influenza outbreak. Doubts arose surrounding the shelf-life of the reconstituted product. As a result of these problems, the first supply of the drug reached San Luis Potosí 11 days after the influenza outbreak had begun. Furthermore, dispensing criteria at the state level had to be changed in conformity with the availability of oseltamivir. LESSONS LEARNT: Antiviral demand forecasts should be based on clearly defined distribution and dispensing criteria and decentralization of some of the medication stockpile should be considered. Mexico's national pandemic preparedness plan needs to be updated in accordance with the lessons learnt in 2009 to improve strategic stockpile management and ensure rapid delivery of oseltamivir to the population.
PROBLEM: During an influenza outbreak or pandemic, timely access to antivirals is essential to reduce disease severity and transmission. Best practices in antiviral procurement, storage, distribution, prescription and dispensing must be followed for prompt drug delivery. APPROACH: Mexico implemented a national pandemic preparedness plan in 2006 and created a strategic antiviral stockpile. Oseltamivir powder was stored centrally in bulk for distribution to all 31 states and the capital district during an influenza outbreak. LOCAL SETTING: San Luis Potosí, in northern Mexico, was one of the states most intensely affected by the 2009 H1N1 influenza outbreak. RELEVANT CHANGES: The oseltamivir powder was meant to be reconstituted locally but had to be reconstituted centrally during the 2009 influenza outbreak. Doubts arose surrounding the shelf-life of the reconstituted product. As a result of these problems, the first supply of the drug reached San Luis Potosí 11 days after the influenza outbreak had begun. Furthermore, dispensing criteria at the state level had to be changed in conformity with the availability of oseltamivir. LESSONS LEARNT: Antiviral demand forecasts should be based on clearly defined distribution and dispensing criteria and decentralization of some of the medication stockpile should be considered. Mexico's national pandemic preparedness plan needs to be updated in accordance with the lessons learnt in 2009 to improve strategic stockpile management and ensure rapid delivery of oseltamivir to the population.
Authors: Luis R Carrasco; Vernon J Lee; Mark I Chen; David B Matchar; James P Thompson; Alex R Cook Journal: J R Soc Interface Date: 2011-02-04 Impact factor: 4.118
Authors: Fatimah S Dawood; Seema Jain; Lyn Finelli; Michael W Shaw; Stephen Lindstrom; Rebecca J Garten; Larisa V Gubareva; Xiyan Xu; Carolyn B Bridges; Timothy M Uyeki Journal: N Engl J Med Date: 2009-05-07 Impact factor: 91.245
Authors: Alejandro Gómez-Gómez; Martin Magaña-Aquino; Christian Garcia-Sepúlveda; Uciel R Ochoa-Pérez; Reynaldo Falcón-Escobedo; Andreu Comas-García; Saray Aranda-Romo; Hugo I Contreras-Treviño; Paulina V Jimenéz-Rico; Mario A Banda-Barbosa; Félix Dominguez-Paulin; J Mario Bernal-Blanco; Luis F Peréz-González; Daniel E Noyola Journal: Emerg Infect Dis Date: 2010-01 Impact factor: 6.883
Authors: Mario Bermúdez de León; Rafael B R León-Cachón; Beatriz Silva-Ramírez; Rosa Nelly González-Ríos; Brenda Escobedo-Guajardo; Roberto Leyva-Parra; Benjamín Tovar-Cisneros; Everardo González-González; Abdiel Alvarado-Díaz; Ofelia Vázquez-Monsiváis; Viviana Mata-Tijerina; Lorena Puente-Lugo; Erick Álvarez-Galván; María José Currás-Tuala; Miguel Aguado-Barrera; Fabiola Castorena-Torres; Juan Manuel Alcocer-González; Guillermo Elizondo; Ana María Salinas-Martínez Journal: Pharmacogenomics J Date: 2020-02-04 Impact factor: 3.550